Tags

Type your tag names separated by a space and hit enter

Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds.
Eur J Clin Invest. 2007 Mar; 37(3):171-9.EJ

Abstract

All stages of atherosclerosis have been identified as a chronic vascular inflammatory disease. In the last few years there is increasing evidence that endogenous lysophospholipids such as sphingosine-1-phosphate (S1P) have potent anti-inflammatory properties. The S1P analogue FTY720 that has been developed as a potent, orally active, immunosuppressant in the field of transplantation and autoimmune disease has interesting effects on inflammatory processes in the arterial vessel wall. S1P targets five specific S1P receptors (S1P(1-5)), which are ubiquitously expressed. S1P(1-3) receptor expression is identified in arterial vessels. S1P and FTY720 show potent silencing effects on some vascular proinflammatory mechanisms in endothelial and vascular smooth muscle cells. In addition, the interaction of monocytes with the vessel wall is inhibited. As shown recently, FTY720 can effectively reduce the progression of atherosclerosis in apolipoprotein E-deficient mice having a high-cholesterol diet. It is not entirely clear which S1P receptor subtype is mainly involved in this process. However, it is currently speculated that the S1P(3) and probably the S1P(1) is involved in the anti-atherosclerotic effects of FTY720. This review summarizes the current knowledge about S1P- and FTY720-effects on mechanisms of vascular inflammatory disease. In addition S1P receptor subtypes are identified which might be interesting for molecular drug targeting.

Authors+Show Affiliations

Charite - Universitätsmedizin Berlin, Campus Benjamin Franklin, Med. Klinik mit Schwerpunkt Nephrologie, Berlin, Germany.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

17359484

Citation

Tölle, M, et al. "Sphingosine-1-phosphate and FTY720 as Anti-atherosclerotic Lipid Compounds." European Journal of Clinical Investigation, vol. 37, no. 3, 2007, pp. 171-9.
Tölle M, Levkau B, Kleuser B, et al. Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. Eur J Clin Invest. 2007;37(3):171-9.
Tölle, M., Levkau, B., Kleuser, B., & van der Giet, M. (2007). Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. European Journal of Clinical Investigation, 37(3), 171-9.
Tölle M, et al. Sphingosine-1-phosphate and FTY720 as Anti-atherosclerotic Lipid Compounds. Eur J Clin Invest. 2007;37(3):171-9. PubMed PMID: 17359484.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Sphingosine-1-phosphate and FTY720 as anti-atherosclerotic lipid compounds. AU - Tölle,M, AU - Levkau,B, AU - Kleuser,B, AU - van der Giet,M, PY - 2007/3/16/pubmed PY - 2007/6/30/medline PY - 2007/3/16/entrez SP - 171 EP - 9 JF - European journal of clinical investigation JO - Eur. J. Clin. Invest. VL - 37 IS - 3 N2 - All stages of atherosclerosis have been identified as a chronic vascular inflammatory disease. In the last few years there is increasing evidence that endogenous lysophospholipids such as sphingosine-1-phosphate (S1P) have potent anti-inflammatory properties. The S1P analogue FTY720 that has been developed as a potent, orally active, immunosuppressant in the field of transplantation and autoimmune disease has interesting effects on inflammatory processes in the arterial vessel wall. S1P targets five specific S1P receptors (S1P(1-5)), which are ubiquitously expressed. S1P(1-3) receptor expression is identified in arterial vessels. S1P and FTY720 show potent silencing effects on some vascular proinflammatory mechanisms in endothelial and vascular smooth muscle cells. In addition, the interaction of monocytes with the vessel wall is inhibited. As shown recently, FTY720 can effectively reduce the progression of atherosclerosis in apolipoprotein E-deficient mice having a high-cholesterol diet. It is not entirely clear which S1P receptor subtype is mainly involved in this process. However, it is currently speculated that the S1P(3) and probably the S1P(1) is involved in the anti-atherosclerotic effects of FTY720. This review summarizes the current knowledge about S1P- and FTY720-effects on mechanisms of vascular inflammatory disease. In addition S1P receptor subtypes are identified which might be interesting for molecular drug targeting. SN - 0014-2972 UR - https://www.unboundmedicine.com/medline/citation/17359484/Sphingosine_1_phosphate_and_FTY720_as_anti_atherosclerotic_lipid_compounds_ L2 - https://doi.org/10.1111/j.1365-2362.2007.01776.x DB - PRIME DP - Unbound Medicine ER -